Summary

The Asia-Pacific alpha and beta emitters based radiopharmaceuticals market is expected to reach USD 358.93 million by 2032 from USD 168.86 million in 2024, growing with a substantial CAGR of 9.9% in the forecast period of 2025 to 2032.

Market Segmentation:
Asia-Pacific Alpha and Beta Emitters Based Radiopharmaceuticals Market, By Isotope (Beta Emitters and Alpha Emitters), Sources (Reactor-Produced Isotopes, Generator-Produced Isotopes, and Others), Therapeutic Application (Oncology and Others), Vector Type (Small Molecule Ligands, Peptides, Monoclonal Antibodies, and Others), End User (Hospitals, Radiopharmacies, and Research Institutes), Country (China, Japan, India, South Korea, Australia, Singapore, Indonesia, Thailand, Malaysia, Philippines, Vietnam, Taiwan, and Rest of Asia-Pacific) - Industry Trends and Forecast to 2032
Overview of Asia-Pacific Alpha and Beta Emitters Based Radiopharmaceuticals Market Dynamics:
Drivers
• Increased efficacy of targeted alpha and beta therapies
• Growing adoption of theranostics in personalized medicine
Restraints
• Supply chain and scalability challenges from short isotope half-lives
• Stringent regulatory landscape limiting market flexibility
Opportunities
• Surge in R&D activity expanding radiopharmaceutical applications
• Expansion of Lu-177-PSMA therapy in prostate cancer treatment
Market Players:
The key players operating in the Asia-Pacific alpha and beta emitters based radiopharmaceuticals market are:
• Novartis AG
• Eckert & Ziegler
• ARICEUM THERAPEUTICS
• Bayer AG
• Curium
• Lilly
• Radiopharm Theranostics Limited
• Telix Pharmaceuticals Limited

ページTOPに戻る

Table of Contents

TABLE OF CONTENTS
1 INTRODUCTION 35
1.1 OBJECTIVES OF THE STUDY 35
1.2 MARKET DEFINITION 35
1.3 OVERVIEW OF ASIA-PACIFIC ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET 35
1.4 MARKETS COVERED 37
2 MARKET SEGMENTATION 40
2.1 MARKETS COVERED 40
2.2 GEOGRAPHICAL SCOPE 41
2.3 YEARS CONSIDERED FOR THE STUDY 42
2.4 CURRENCY AND PRICING 42
2.5 DBMR TRIPOD DATA VALIDATION MODEL 43
2.6 MULTIVARIATE MODELLING 46
2.7 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 47
2.8 DBMR MARKET POSITION GRID 48
2.9 VENDOR SHARE ANALYSIS 49
2.10 END USER MARKET COVERAGE GRID 50
2.11 SECONDARY SOURCES 51
2.12 ASSUMPTIONS 51
3 EXECUTIVE SUMMARY 52
4 PREMIUM INSIGHT 58
4.1 PORTER’S FIVE FORCES 59
4.2 PESTEL ANALYSIS 60
4.3 PIPELINE 61
4.4 SUPPLY CHAIN ECOSYSTEM 66
4.4.1 PROMINENT COMPANIES 66
4.4.2 SMALL & MEDIUM SIZE COMPANIES 66
4.4.3 END USERS 66
4.5 INDUSTRY INSIGHTS: 67
4.5.1 MICRO AND MACRO ECONOMIC FACTORS 67
4.5.2 KEY PRICING STRATEGIES 68
4.6 MARKETED DRUG ANALYSIS 69
4.6.1 DRUG 69
4.6.1.1 BRAND NAME 69
4.6.1.2 GENERIC NAME 69
4.6.2 THERAPEUTIC INDICATION 69
4.6.3 PHARMACOLOGICAL CLASS OF THE DRUG 69
4.6.4 DRUG PRIMARY INDICATION 69
4.6.5 MARKET STATUS 69
4.6.6 MEDICATION TYPE 70
4.6.7 DRUG DOSAGE FORM 70
4.6.8 DOSAGES AVAILABILITY 70
4.6.9 PACKAGING TYPE 70
4.6.10 DRUG ROUTE OF ADMINISTRATION 70
4.6.11 DOSING FREQUENCY 70
4.6.12 DRUG INSIGHT 70
4.6.13 OVERVIEW OF DRUG DEVELOPMENT ACTIVITIES 71
4.6.13.1 FORECAST MARKET OUTLOOK 71
4.6.13.2 CROSS COMPETITION 71
4.6.13.3 THERAPEUTIC PORTFOLIO 71
4.6.13.4 CURRENT DEVELOPMENT SCENARIO 71
4.7 HEALTHCARE TARIFFS IMPACT ANALYSIS 72
4.7.1 OVERVIEW 72
4.7.2 TARIFF STRUCTURES 72
4.7.2.1 ASIA-PACIFIC VS. REGIONAL TARIFF STRUCTURES 72
4.7.2.2 UNITED STATES: MEDICARE/MEDICAID TARIFF POLICIES, CMS PRICING MODELS 72
4.7.2.3 EUROPEAN UNION: CROSS-BORDER TARIFF REGULATIONS, REIMBURSEMENT POLICIES 72
4.7.2.4 ASIA-PACIFIC: GOVERNMENT-IMPOSED TARIFFS ON IMPORTED MEDICAL PRODUCTS 72
4.7.2.5 EMERGING MARKETS: CHALLENGES IN TARIFF IMPLEMENTATION 73
4.7.3 PHARMACEUTICAL TARIFFS AND TRADE BARRIERS 73
4.7.3.1 IMPORT DUTIES ON PRESCRIPTION DRUGS VS. GENERICS 73
4.7.3.2 IMPACT ON DRUG AFFORDABILITY AND ACCESS 73
4.7.3.3 KEY TRADE AGREEMENTS AFFECTING PHARMACEUTICAL TARIFFS 73
4.8 IMPACT OF HEALTHCARE TARIFFS ON PROVIDERS AND PATIENTS 73
4.8.1.1 COST BURDEN ON HOSPITALS AND HEALTHCARE FACILITIES 73
4.8.1.2 EFFECT ON PATIENT AFFORDABILITY AND INSURANCE COVERAGE 73
4.8.1.3 TARIFFS AND THEIR ROLE IN MEDICAL TOURISM 74
4.8.2 TRADE AGREEMENTS AND HEALTHCARE TARIFFS 74
4.8.2.1 WTO REGULATIONS ON HEALTHCARE TARIFFS 74
4.8.2.2 IMPACT OF TRADE WARS ON THE HEALTHCARE SUPPLY CHAIN 74
4.8.2.3 ROLE OF FREE TRADE AGREEMENTS (FTAS) IN REDUCING TARIFFS 74
4.8.3 IMPACT OF TARIFFS ON HEALTHCARE COSTS AND ACCESSIBILITY 74
4.8.4 IMPORTANCE OF TARIFFS IN THE HEALTHCARE SECTOR 74
4.9 EPIDEMIOLOGY OVERVIEW 75
4.9.1 INCIDENCE OF ALL CANCERS BY GENDER 75
4.9.2 TREATMENT RATE 76
4.9.3 MORTALITY RATE 76
4.9.4 DRUG ADHERENCE AND THERAPY SWITCH MODEL 77
4.9.5 PATIENT TREATMENT SUCCESS RATES 77
5 REGULATORY FRAMEWORK 79
5.1 REGULATORY FRAMEWORK OVERVIEW FOR THE ASIA-PACIFIC ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET 83
5.1.1 GEOGRAPHIES’ EASE OF REGULATORY APPROVAL 83
5.1.2 REGULATORY APPROVAL PATHWAYS 84
5.1.3 LICENSING AND REGISTRATION 84
5.1.4 POST-MARKETING SURVEILLANCE 85
5.1.5 GOOD MANUFACTURING PRACTICES (GMPS) GUIDELINES 85
6 MARKET OVERVIEW 87
6.1 DRIVERS 89
6.1.1 INCREASED EFFICACY OF TARGETED ALPHA AND BETA THERAPIES 89
6.1.2 GROWING ADOPTION OF THERANOSTICS IN PERSONALIZED MEDICINE 89
6.1.3 RISING CLINICAL DEMAND FOR ALPHA-BASED RADIOTHERAPIES 90
6.1.4 RISING CHRONIC DISEASE BURDEN DRIVING RADIOPHARMACEUTICAL DEMAND 91
6.2 RESTRAINTS 92
6.2.1 SUPPLY CHAIN AND SCALABILITY CHALLENGES FROM SHORT ISOTOPE HALF-LIVES 92
6.2.2 STRINGENT REGULATORY LANDSCAPE LIMITING MARKET FLEXIBILITY 92
6.2.3 SAFETY AND EXPOSURE RISKS IN RADIOPHARMACEUTICAL USE 93
6.3 OPPORTUNITIES 94
6.3.1 SURGE IN R&D ACTIVITY EXPANDING RADIOPHARMACEUTICAL APPLICATIONS 94
6.3.2 EXPANSION OF LU-177-PSMA THERAPY IN PROSTATE CANCER TREATMENT 95
6.3.3 STRATEGIC COLLABORATIONS DRIVING RADIOPHARMACEUTICAL INNOVATION 95
6.4 CHALLENGES 96
6.4.1 HIGH COST OF DEVELOPMENT AND IMPLEMENTATION OF RADIOPHARMACEUTICALS 96
6.4.2 SHORTAGE OF SKILLED WORKFORCE IN NUCLEAR MEDICINE AND RADIOCHEMISTRY 97
7 ASIA-PACIFIC ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY ISOTOPE 99
7.1 OVERVIEW 100
7.2 BETA EMITTERS 103
7.2.1 LUTETIUM-177 103
7.2.2 TERBIUM-161 103
7.3 ALPHA EMITTERS 104
7.3.1 ACTINIUM-225 104
7.3.2 LEAD -212 104
8 ASIA-PACIFIC ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY SOURCES 105
8.1 OVERVIEW 106
8.2 REACTOR-PRODUCED ISOTOPES 109
8.3 GENERATOR-PRODUCED ISOTOPES 109
8.4 OTHERS 110
9 ASIA-PACIFIC ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY THERAPEUTIC APPLICATION 111
9.1 OVERVIEW 112
9.2 ONCOLOGY 115
9.2.1 PROSTATE CANCER 116
9.2.2 NEUROENDOCRINE TUMORS 116
9.2.3 LIVER CANCER 116
9.2.4 BRAIN TUMORS 116
9.2.5 BREAST CANCER 116
9.2.6 LEUKEMIA 116
9.3 OTHERS 116
10 ASIA-PACIFIC ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY VECTOR TYPE 117
10.1 OVERVIEW 118
10.2 SMALL MOLECULE LIGANDS 121
10.3 PEPTIDES 121
10.4 MONOCLONAL ANTIBODIES 122
10.5 OTHERS 122
11 ASIA-PACIFIC ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY END USER 123
11.1 OVERVIEW 124
11.2 HOSPITALS 127
11.2.1 ONCOLOGY CENTERS 127
11.2.2 NUCLEAR MEDICINE DEPARTMENTS 127
11.3 RADIOPHARMACIES 128
11.4 RESEARCH INSTITUTES 128
12 ASIA-PACIFIC ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY REGION 129
12.1 ASIA-PACIFIC 131
12.1.1 CHINA 136
12.1.2 AUSTRALIA 139
12.1.3 JAPAN 142
12.1.4 SOUTH KOREA 145
12.1.5 SINGAPORE 148
12.1.6 INDIA 151
12.1.7 INDONESIA 154
12.1.8 PHILIPPINES 157
12.1.9 THAILAND 160
12.1.10 MALAYSIA 163
12.1.11 VIETNAM 166
12.1.12 TAIWAN 169
12.1.13 REST OF ASIA-PACIFIC 172
13 ASIA-PACIFIC ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET: COMPANY LANDSCAPE 173
13.1 COMPANY SHARE ANALYSIS: ASIA-PACIFIC 173
14 SWOT ANALYSIS 174
15 COMPANY PROFILES 175
15.1 NOVARTIS AG 175
15.1.1 COMPANY SNAPSHOT 175
15.1.2 REVENUE ANALYSIS 176
15.1.3 COMPANY SHARE ANALYSIS 176
15.1.4 PRODUCT PORTFOLIO 177
15.1.5 RECENT DEVELOPMENTS 177
15.2 ECKERT & ZIEGLER 178
15.2.1 COMPANY SNAPSHOT 178
15.2.2 REVENUE ANALYSIS 178
15.2.3 COMPANY SHARE ANALYSIS 179
15.2.4 PRODUCT PORTFOLIO 179
15.2.5 RECENT DEVELOPMENTS 180
15.3 ITM ISOTOPE TECHNOLOGIES MUNICH SE 181
15.3.1 COMPANY SNAPSHOT 181
15.3.2 COMPANY SHARE ANALYSIS 181
15.3.3 PRODUCT PORTFOLIO 182
15.3.4 RECENT DEVELOPMENT 182
15.4 SHINE TECHNOLOGIES, LLC 183
15.4.1 COMPANY SNAPSHOT 183
15.4.2 COMPANY SHARE ANALYSIS 183
15.4.3 PRODUCT PORTFOLIO 184
15.4.4 RECENT DEVELOPMENT 184
15.5 ACTINIUM PHARMACEUTICALS, INC. 185
15.5.1 COMPANY SNAPSHOT 185
15.5.2 PIPELINE PRODUCT PORTFOLIO 185
15.5.3 RECENT DEVELOPMENTS 186
15.6 ALPHA TAU MEDICAL LTD. 187
15.6.1 COMPANY SNAPSHOT 187
15.6.2 PIPELINE PRODUCT PORTFOLIO 187
15.6.3 RECENT DEVELOPMENT 187
15.7 ARICEUM THERAPEUTICS 188
15.7.1 COMPANY SNAPSHOT 188
15.7.2 PIPELINE PRODUCT PORTFOLIO 188
15.7.3 RECENT DEVELOPMENT 188
15.8 BAYER AG 189
15.8.1 COMPANY SNAPSHOT 189
15.8.2 REVENUE ANALYSIS 189
15.8.3 PIPELINE PRODUCT PORTFOLIO 190
15.8.4 RECENT DEVELOPMENT 190
15.9 CURIUM 191
15.9.1 COMPANY SNAPSHOT 191
15.9.2 PIPELINE PRODUCT PORTFOLIO 191
15.9.3 RECENT DEVELOPMENT 191
15.10 IONETIX CORPORATION 192
15.10.1 COMPANY SNAPSHOT 192
15.10.2 PIPELINE PRODUCT PORTFOLIO 192
15.10.3 RECENT DEVELOPMENT 192
15.11 ISOTOPIA 193
15.11.1 COMPANY SNAPSHOT 193
15.11.2 PIPELINE PRODUCT PORTFOLIO 193
15.11.3 RECENT DEVELOPMENT 193
15.12 LANTHEUS 194
15.12.1 COMPANY SNAPSHOT 194
15.12.2 REVENUE ANALYSIS 194
15.12.3 PIPELINE PRODUCT PORTFOLIO 195
15.12.4 RECENT DEVELOPMENT 196
15.13 LILLY 197
15.13.1 COMPANY SNAPSHOT 197
15.13.2 REVENUE ANALYSIS 197
15.13.3 PIPELINE PRODUCT PORTFOLIO 198
15.14 NIOWAVE 199
15.14.1 COMPANY SNAPSHOT 199
15.14.2 PIPELINE PRODUCT PORTFOLIO 199
15.14.3 RECENT DEVELOPMENT 199
15.15 NMR 200
15.15.1 COMPANY SNAPSHOT 200
15.15.2 PIPELINE PRODUCT PORTFOLIO 200
15.15.3 RECENT DEVELOPMENT 200
15.16 ONCOINVENT 201
15.16.1 COMPANY SNAPSHOT 201
15.16.2 PIPELINE PRODUCT PORTFOLIO 201
15.16.3 RECENT DEVELOPMENT 201
15.17 ORANO GROUP 202
15.17.1 COMPANY SNAPSHOT 202
15.17.2 REVENUE ANALYSIS 202
15.17.3 PIPELINE PRODUCT PORTFOLIO 203
15.17.4 RECENT DEVELOPMENT 204
15.18 RADIOPHARM THERANOSTICS LIMITED 205
15.18.1 COMPANY SNAPSHOT 205
15.18.2 PIPELINE PRODUCT PORTFOLIO 205
15.18.3 RECENT DEVELOPMENT 206
15.19 TELIX PHARMACEUTICALS LIMITED 207
15.19.1 COMPANY SNAPSHOT 207
15.19.2 REVENUE ANALYSIS 207
15.19.3 PIPELINE PRODUCT PORTFOLIO 208
15.19.4 RECENT DEVELOPMENT 209
15.20 TERTHERA 210
15.20.1 COMPANY SNAPSHOT 210
15.20.2 PIPELINE PRODUCT PORTFOLIO 210
15.20.3 RECENT DEVELOPMENT 210
15.20.4 RECENT DEVELOPMENT 210
16 QUESTIONNAIRE 211
17 RELATED REPORTS 214